These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 24142032)

  • 1. A comparison of outcomes between OKT3 and antithymocyte globulin for treatment of steroid-resistant rejection in hepatitis C liver transplant recipients.
    Benjamin MM; Dasher KJ; Trotter JF
    Transplantation; 2014 Feb; 97(4):470-3. PubMed ID: 24142032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation.
    Rosen HR; Shackleton CR; Higa L; Gralnek IM; Farmer DA; McDiarmid SV; Holt C; Lewin KJ; Busuttil RW; Martin P
    Am J Gastroenterol; 1997 Sep; 92(9):1453-7. PubMed ID: 9317061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy.
    Cantarovich M; Latter DA; Loertscher R
    Clin Transplant; 1997 Aug; 11(4):316-21. PubMed ID: 9267721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-shot antithymocyte globulin (ATG) induction for pancreas/kidney transplantation: ATG-Fresenius versus Thymoglobulin.
    Schulz T; Papapostolou G; Schenker P; Kapischke M
    Transplant Proc; 2005 Mar; 37(2):1301-4. PubMed ID: 15848703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OKT3 therapy in addition to tacrolimus is associated with improved long-term function in patients with steroid refractory renal allograft rejection.
    Patschan D; Kribben A; Pietruck F; Lutz J; Binek M; Philipp T; Heemann U; Witzke O
    Nephron Clin Pract; 2006; 103(3):c94-9. PubMed ID: 16534238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss.
    Bahra M; Neumann UP; Jacob D; Langrehr JM; Neuhaus P
    Transplant Proc; 2005 May; 37(4):1700-2. PubMed ID: 15919436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithymocyte globulin induction therapy in hepatitis C-positive liver transplant recipients.
    Horton PJ; Tchervenkov J; Barkun JS; Rochon C; Chaudhury PK; Znajda TL; Martinie JB; Metrakos P
    J Gastrointest Surg; 2005; 9(7):896-902. PubMed ID: 16137581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OKT3 treatment for steroid-resistant acute rejection in kidney transplantation.
    Sevmis S; Emiroglu R; Karakayali F; Yagmurdur MC; Dalgic A; Moray G; Haberal M
    Transplant Proc; 2005 Sep; 37(7):3016-8. PubMed ID: 16213290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steroid-resistant acute rejections after liver transplant.
    Aydogan C; Sevmis S; Aktas S; Karakayali H; Demirhan B; Haberal M
    Exp Clin Transplant; 2010 Jun; 8(2):172-7. PubMed ID: 20565375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of steroid-resistant rejection with tacrolimus prior to OKT3 in liver transplant recipients.
    Millis JM; Bruce DS; Newell KA; Piper JB; Woodle ES; Seaman DS; Baker AL; Hart J; Dasgupta K; Thistlethwaite JR
    Transplant Proc; 1996 Apr; 28(2):1014. PubMed ID: 8623213
    [No Abstract]   [Full Text] [Related]  

  • 11. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients.
    Mariat C; Alamartine E; Diab N; de Filippis JP; Laurent B; Berthoux F
    Transpl Int; 1998; 11(3):231-6. PubMed ID: 9638854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic therapy for rejection after cardiac transplantation. A comparison of rabbit antithymocyte globulin and OKT3.
    Kirklin JK; Bourge RC; White-Williams C; Naftel DC; Thomas FT; Thomas JM; Phillips MG
    J Thorac Cardiovasc Surg; 1990 Apr; 99(4):716-24. PubMed ID: 2108282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation.
    Sheiner PA; Schwartz ME; Mor E; Schluger LK; Theise N; Kishikawa K; Kolesnikov V; Bodenheimer H; Emre S; Miller CM
    Hepatology; 1995 Jan; 21(1):30-4. PubMed ID: 7806166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylaxis of heart transplant rejection with either antithymocyte globulin-, Minnesota antilymphocyte globulin-, or an OKT3-based protocol.
    Ladowski JS; Dillon T; Schatzlein MH; Peterson AC; Deschner WP; Beatty L; Sullivan M; Scheeringa RH; Clark WR
    J Cardiovasc Surg (Torino); 1993 Apr; 34(2):135-40. PubMed ID: 8320247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early steroid-resistant rejection following orthotopic liver transplantation: new aspects of treatment with FK 506 instead of OKT3?
    Dé P; Bechstein WO; Blumhardt G; Lange D; Schattenfroh N; Neuhaus P
    Transplant Proc; 1993 Aug; 25(4):2693-4. PubMed ID: 7689279
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-lymphocyte therapy successfully controls late "cholestatic" rejection in pediatric liver transplant recipients.
    Kerkar N; Morotti RA; Iyer K; Arnon R; Miloh T; Sturdevant M; Suchy F; Florman S; Emre S
    Clin Transplant; 2011; 25(6):E584-91. PubMed ID: 21919961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and outcome of OKT3 treatment for early steroid-resistant rejection following hepatic transplantation.
    Lange D; Bechstein WO; Blumhardt G; Lemmens P; Schattenfroh N; Neuhaus P
    Transplant Proc; 1993 Apr; 25(2):1870-1. PubMed ID: 8470207
    [No Abstract]   [Full Text] [Related]  

  • 18. A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C.
    Margarit C; Bilbao I; Castells L; Lopez I; Pou L; Allende E; Escartin A
    Transpl Int; 2005 Dec; 18(12):1336-45. PubMed ID: 16297052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective randomized trial of OKT3- versus horse antithymocyte globulin-based immunosuppressive prophylaxis in heart transplantation.
    Costanzo-Nordin MR; O'Sullivan EJ; Johnson MR; Winters GL; Pifarre R; Radvany R; Zucker MJ; Scanlon PJ; Robinson JA
    J Heart Transplant; 1990; 9(3 Pt 2):306-15. PubMed ID: 2113094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OKT3 induction and steroid-free maintenance immunosuppression for treatment of high-risk heart transplant recipients.
    Prieto M; Lake KD; Pritzker MR; Jorgensen CR; Arom KV; Love KR; Emery RW
    J Heart Lung Transplant; 1991; 10(6):901-11. PubMed ID: 1661608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.